BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Entry into a Material Definitive Agreement

BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.  Entry into a Material Definitive Agreement

Story continues below

On December 14, 2016, BioPharmX, Inc., a Nevada corporation and wholly-owned subsidiary of BioPharmX Corporation (“Company”), and Refuge Biotechnologies, Inc., a Delaware corporation, entered into a Sublease Agreement (“Sublease”) for the lease of approximately 12,066 square feet of office and laboratory space located at 1505 Adams Drive, Menlo Park, California, which will replace the Company’s current corporate headquarters.  This facility will serve as the new principal executive office and laboratory for the Company.  The term of the lease is for one year commencing on December 15, 2016.  The Company’s monthly base rent obligation is $51,280 and the Company will also be obligated to pay its proportionate share of certain expenses associated with the maintenance, repair and operation of the facility.

The foregoing description is qualified in its entirety by reference to the Sublease, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits


Exhibit No.Description

10.1 Sublease agreement between BioPharmX, Inc. and Refuge Biotechnologies, Inc., dated December 14, 2016.



BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.


BIOPHARMX CORPORATION (NYSEMKT:BPMX) closed its last trading session down -0.035 at 0.365 with 924,022 shares trading hands.

An ad to help with our costs